BACKGROUND: Jumping translocations (JT) are uncommon cytogenetic abnormalities involving nonreciprocal translocations of a single donor chromosome onto 2 or more chromosomes. The clinical characteristics and prognosis of JTs in @entity1 with @entity5 are not well described. MATERIALS AND METHODS: We searched our cytogenetic database from 2003 to 2014 to identify cases of @entity5 associated with a JT. These cases were cross-referenced with our clinical databases to determine @entity1 characteristics, response to treatment and overall survival. RESULTS: We identified 10 @entity1 with @entity5 and a JT: 4 cases of @entity3052 with @entity2590 -related changes, 4 cases of @entity2590 , and 2 cases of postpolycythemia @entity4018 . The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late occurrence, with a median time to JT development of 24.9 months (range, 0-248 months) from diagnosis. The overall response to treatment was poor, with no @entity1 experiencing a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% confidence interval, 2.5-15.5) after identification of a JT. CONCLUSION: The acquisition of a JT in @entity1 with @entity5 appears to be a late event and is associated with @entity2590 . In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to @entity3052 , and short overall survival.

Jumping Translocations in XXXX Associated With Treatment Resistance and Poor Survival.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['myeloid malignancies'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'myelodysplasia'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia'] @entity4018 :: ('MESH:D055728', 'Disease') :: ['myelofibrosis']
@entity5 :: (MESH:D009369,Disease) :: ['Myeloid Malignancies']
